Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

8.78
-0.1000-1.13%
Volume:97.02K
Turnover:838.65K
Market Cap:801.69M
PE:-6.23
High:8.78
Open:8.74
Low:8.53
Close:8.88
Loading ...

Myriad Genetics Initiated at Buy by Craig-Hallum

Dow Jones
·
13 Feb

Myriad Genetics initiated with a Buy at Craig-Hallum

TIPRANKS
·
12 Feb

MYGN Stock Might Rise on Collaboration With CancerCARE

Zacks
·
11 Feb

Myriad Genetics management to meet with BTIG

TIPRANKS
·
07 Feb

Myriad Genetics and Cancercare for Life Announce Agreement to Advance Access to Myrisk With Riskscore Hereditary Cancer Test

THOMSON REUTERS
·
06 Feb

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

GlobeNewswire
·
06 Feb

Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay

MT Newswires Live
·
06 Feb

Myriad Genetics issued two new patents from USPTO

TIPRANKS
·
06 Feb

BRIEF-Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay

Reuters
·
06 Feb

Myriad Genetics Announces Two New Patents Granted for Its Molecular Residual Disease (Mrd) Assay

THOMSON REUTERS
·
06 Feb

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

GlobeNewswire
·
06 Feb

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and Myrisk Hereditary Cancer Tests Through Bxlink Integration

THOMSON REUTERS
·
05 Feb

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

GlobeNewswire
·
05 Feb

Biote Announces CEO Retirement and Succession Plan

Business Wire
·
31 Jan

Myriad Genetics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
30 Jan

Myriad Genetics price target lowered to $14 from $24 at Piper Sandler

TIPRANKS
·
30 Jan